Only 1 strongly influential trial was identified; the OV-12 trial23 investigated tanomastat as maintenance therapy, which was interrupted by Bayer owing to negative results in other cancer types, and follow-up was stopped23; progression was assessed using CT scans after initial increase of CA125 levels. This evidence concerns the gene MUC16 and cancer.